Biofrontera AG (B8F):企業の財務・戦略的SWOT分析

◆英語タイトル:Biofrontera AG (B8F) - Financial and Strategic SWOT Analysis Review
◆商品コード:GDPH22166FSA
◆発行会社(調査会社):GlobalData
◆発行日:2020年12月
◆ページ数:49
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:ドイツ
◆産業分野:Pharmaceuticals and Healthcare
◆販売価格オプション(消費税別)
Site License(同一事業所内共有可)USD250 ⇒換算¥35,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD375 ⇒換算¥52,500見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Biofrontera AG (B8F) – Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.
The profile contains critical company information including:

- Business description – A detailed description of the company’s operations and business divisions.
- Corporate strategy – Analyst’s summarization of the company’s business strategy.
- SWOT Analysis – A detailed analysis of the company’s strengths, weakness, opportunities and threats.
- Company history – Progression of key events associated with the company.
- Major products and services – A list of major products, services and brands of the company.
- Key competitors – A list of key competitors to the company.
- Key employees – A list of the key executives of the company.
- Executive biographies – A brief summary of the executives’ employment history.
- Key operational heads – A list of personnel heading key departments/functions.
- Important locations and subsidiaries – A list and contact details of key locations and subsidiaries of the company.
- Detailed financial ratios for the past five years – The latest financial ratios derived from the annual financial statements published by the company with 5 years history.
- Interim ratios for the last five interim periods – The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.

Highlights

Biofrontera AG (Biofrontera) is a biopharmaceutical company that develops and markets dermatological medications and medical cosmetics. The company’s products comprise Ameluz, BF-RhodoLED, Xepi, Aktipak and Belixos. Its prescription drug Ameluz is used for the treatment of skin disease actinic keratosis. Biofrontera’s BF-RhodoLED is a lamp used for photodynamic therapy with LEDs emitting red light. Belixos is a cosmetic product,indicated for regenerative care of reddened and inflamed skin. Its Belixos line of products include Belixos creme, Belixos liquid, Belixos gel, and Belixos protect. The company distributes its products through pharmaceutical wholesalers and licensing partners. Biofrontera is headquartered in Leverkusen, Germany.

Biofrontera AG Key Recent Developments

Jul 23,2020: Supervisory Board of Biofrontera renews management board appointment
May 19,2020: Biofrontera : Biofrontera reports Q1 2020 financial results
May 13,2020: Biofrontera AG: Biofrontera dismisses case against Dusa Pharmaceuticals in California state court
Apr 20,2020: Biofrontera reports full year 2019 financial results
Apr 17,2020: Biofrontera reports preliminary unaudited sales revenue for the first three months of 2020

Key benefits of buying this profile include:

You get detailed information about the company and its operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.

Understand and respond to your competitors’ business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company.
- The company’s core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.

Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably.
- Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.

Scout for potential investments and acquisition targets, with detailed insight into the companies’ strategic, financial and operational performance.
- Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.

Gain key insights into the company for academic or business research.
- Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.

Note: Some sections may be missing if data is unavailable for the company

【レポートの目次】

Table of Contents
List of Tables
List of Figures
Section 1 – About the Company
Biofrontera AG – Key Facts
Biofrontera AG – Key Employees
Biofrontera AG – Key Employee Biographies
Biofrontera AG – Major Products and Services
Biofrontera AG – History
Biofrontera AG – Company Statement
Biofrontera AG – Locations And Subsidiaries
Head Office
Other Locations & Subsidiaries
Section 2 – Company Analysis
Company Overview
Biofrontera AG – Business Description
Geographical Segment: Europe
Performance
Geographical Segment: Germany
Performance
Geographical Segment: Other regions
Performance
Geographical Segment: The US
Performance
R&D Overview
Biofrontera AG – SWOT Analysis
SWOT Analysis – Overview
Biofrontera AG – Strengths
Biofrontera AG – Weaknesses
Biofrontera AG – Opportunities
Biofrontera AG – Threats
Biofrontera AG – Key Competitors
Section 3 – Company Financial Ratios
Financial Ratios – Capital Market Ratios
Financial Ratios – Annual Ratios
Performance Chart
Financial Performance
Financial Ratios – Interim Ratios
Financial Ratios – Ratio Charts
Section 4 – Company’s Lifesciences Financial Deals and Alliances
Biofrontera AG, Pharmaceuticals & Healthcare, Deals By Year, 2014 to YTD 2020
Biofrontera AG, Pharmaceuticals & Healthcare, Deals By Type, 2014 to YTD 2020
Biofrontera AG, Recent Deals Summary
Section 5 – Company’s Recent Developments
Jul 23, 2020: Supervisory Board of Biofrontera renews management board appointment
May 19, 2020: Biofrontera : Biofrontera reports Q1 2020 financial results
May 13, 2020: Biofrontera AG: Biofrontera dismisses case against Dusa Pharmaceuticals in California state court
Apr 20, 2020: Biofrontera reports full year 2019 financial results
Apr 17, 2020: Biofrontera reports preliminary unaudited sales revenue for the first three months of 2020
Jan 31, 2020: Organizational restructuring of Biofrontera and resignation of chief commercial officer Christoph Dünwald
Jan 06, 2020: Biofrontera strengthens commercial focus with reorganization of its US business
Dec 13, 2019: Biofrontera: Christopher Pearson appointed new Chief Commercial Officer at US subsidiary Biofrontera
Nov 19, 2019: Biofrontera reports third quarter 2019 financial results and revises guidance
Aug 27, 2019: Biofrontera shows robust growth during first six months of 2019
Section 6 – Appendix
Methodology
Ratio Definitions
About GlobalData
Contact Us
Disclaimer

List of Tables
Biofrontera AG, Key Facts
Biofrontera AG, Key Employees
Biofrontera AG, Key Employee Biographies
Biofrontera AG, Major Products and Services
Biofrontera AG, History
Biofrontera AG, Subsidiaries
Biofrontera AG, Key Competitors
Biofrontera AG, Ratios based on current share price
Biofrontera AG, Annual Ratios
Biofrontera AG, Annual Ratios (Cont...1)
Biofrontera AG, Interim Ratios
Biofrontera AG, Pharmaceuticals & Healthcare, Deals By Year, 2014 to YTD 2020
Biofrontera AG, Pharmaceuticals & Healthcare, Deals By Type, 2014 to YTD 2020
Biofrontera AG, Recent Deals Summary
Currency Codes
Capital Market Ratios
Equity Ratios
Profitability Ratios
Cost Ratios
Liquidity Ratios
Leverage Ratios
Efficiency Ratios

★海外企業調査レポート[Biofrontera AG (B8F):企業の財務・戦略的SWOT分析]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • Vertical Pharmaceuticals LLC:製薬・医療:M&Aディール及び事業提携情報
    Summary Vertical Pharmaceuticals LLC (Vertical Pharmaceuticals), a subsidiary of Osmotica Pharmaceutical Corp, is a medicines marketing company that supplies niche prescription medicines. The company offers product category includes women's health and pain management. It provides products such as Co …
  • Merck & Co Inc (MRK):企業の財務・戦略的SWOT分析
    Merck & Co Inc (MRK) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and …
  • Epic Systems Corp:企業の戦略的SWOT分析
    Epic Systems Corp - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and serv …
  • Luxoft Holding Inc:企業の戦略・SWOT・財務情報
    Luxoft Holding Inc - Strategy, SWOT and Corporate Finance Report Summary Luxoft Holding Inc - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and …
  • Henry Schein Inc (HSIC):企業の財務・戦略的SWOT分析
    Henry Schein Inc (HSIC) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses a …
  • China Medical System Holdings Ltd (867):企業の財務・戦略的SWOT分析
    Summary China Medical System Holdings Ltd (CMS) is a pharmaceutical service provider that markets, promotes, and sells prescription drugs to all therapeutic departments in hospitals. The company offers products such as deanxit, ursofalk, augentropfen stulln mono eye-drops, exacin, xinhuosu, salofalk …
  • Biotest AG (BIO)-製薬・医療分野:企業M&A・提携分析
    Summary Biotest AG (Biotest) is a provider of pharmaceutical and biotherapeutic drugs which develops, manufactures and distributes biological medicines through its value chain from preclinical and clinical development to sales. Its main products comprise clotting factors, immunoglobulins, albumin an …
  • CyberOptics Corp (CYBE):企業の財務・戦略的SWOT分析
    Summary CyberOptics Corp (CyberOptics) is a technology company that offers high precision 3D sensors. The company’s products include SMT inspection, semiconductor and MRS sensors. CyberOptics SMT inspection provides solder paste inspection systems, automated optical inspection systems, and software …
  • MakeMyTrip Limited:企業の戦略・SWOT・財務分析
    MakeMyTrip Limited - Strategy, SWOT and Corporate Finance Report Summary MakeMyTrip Limited - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and …
  • mAbxience SA:製薬・医療:M&Aディール及び事業提携情報
    Summary Mabxience SA (mAbxience), a subsidiary of Chemo Espana SA, is a biotechnology company that research, develops and manufactures biosimilar monoclonal antibodies. The company develops biosimilars, which are used for the treatment and prevention of various diseases in onclology such as breast c …
  • Shenzhen Century Plaza Hotel Co., Ltd.:企業の戦略・SWOT・財務情報
    Shenzhen Century Plaza Hotel Co., Ltd. - Strategy, SWOT and Corporate Finance Report Summary Shenzhen Century Plaza Hotel Co., Ltd. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT ana …
  • Innovation Pharmaceuticals Inc (IPIX)-医療機器分野:企業M&A・提携分析
    Summary Innovation Pharmaceuticals Inc (Innovation Pharmaceuticals), formerly Cellceutix Corp is a biopharmaceutical company that discovers and advances medical therapies with dermatology, oncology, anti-inflammatory and antibiotic applications. The company pipeline products include kevetrin for the …
  • Ameriprise Financial, Inc. (AMP):企業の財務・戦略的SWOT分析
    Ameriprise Financial, Inc. (AMP) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and wea …
  • Pacific Drilling SA (PACD):企業の財務・戦略的SWOT分析
    Summary Pacific Drilling SA (Pacific Drilling) is an offshore drilling company that offers ultra deepwater drilling services to the oil and natural gas industry. The company provides contract services for floating rig drilling in ultra deepwater through its drill ships. It rents its drilling rigs, r …
  • Ethypharm SA:製薬・医療:M&Aディール及び事業提携情報
    Summary Ethypharm SA (Ethypharm), a subsidiary of Astorg Partners is a pharmaceutical company that develops and manufactures drugs for the treatment of pain, gastrointestinal, cancer, cardiovascular and central nervous system diseases. The company provides products such as ibuprofen, paracetamol, pr …
  • Mercuria Energy Group Ltd:石油・ガス:M&Aディール及び事業提携情報
    Summary Mercuria Energy Group Ltd (Mercuria Energy) is an independent energy and commodity company that carries out sourcing, supplying and trading of crude oil and refined petroleum products through its subsidiaries. Its portfolio includes petrochemicals, biofuels, environmental products, natural g …
  • Prologis, Inc.:企業のM&A・事業提携・投資動向
    Prologis, Inc. - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's Prologis, Inc. Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and acquisitions (M&A), divestmen …
  • CITIC Pacific Limited:戦略・SWOT・企業財務分析
    CITIC Pacific Limited - Strategy, SWOT and Corporate Finance Report Summary CITIC Pacific Limited - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerin …
  • Joslin Diabetes Center-製薬・医療分野:企業M&A・提携分析
    Summary Joslin Diabetes Center (Joslin) is a healthcare service provider that provides diabetes treatment, research and education services. The centers services include weight management programs, pregnancy program, eye care, diabetes prevention, research, diabetes patient education, adult diabetic …
  • Arris International Plc:企業の戦略・SWOT・財務分析
    Arris International Plc - Strategy, SWOT and Corporate Finance Report Summary Arris International Plc - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service off …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆